噻托溴铵粉吸入剂与沙美特罗替卡松吸入剂对重度COPD患者治疗效果的比较

Comparison of the effects between tiotropiumbromide powder for inhalation and salmeterol and fluticasone propionate inhalation in treatment of patients with severe COPD

目的比较噻托溴铵粉吸入剂与沙美特罗替卡松吸入剂对重度COPD患者的治疗效果。方法选取浙江省新华医院收治的90例重度COPD患者为研究对象。对照组给予沙美特罗替卡松吸入剂治疗，实验组进行噻托溴铵粉吸入剂治疗，18μg，1次/天。比较分析实验组与对照组患者治疗前后FEV1、IC与FVC和不良反应发生情况等临床指标。结果治疗后，实验组FEV1为（1.67±0.43）L，显著高于对照组为（1.29±0.30）L（P＜0.05）。实验组与对照组患者的FVC分别为（2.68±0.60）L与（2.28±0.50）L，比较差异有统计学意义（P＜0.05）。实验组不良反应发生率为13.3%，显著低于对照组的24.4%（P＜0.05）。结论噻托溴铵粉吸入剂与沙美特罗替卡松吸入剂相比，噻托溴铵粉吸入剂对重度COPD患者治疗效果更为理想，不良反应轻微。

Objective To compare the effects of tiotropiumbromide powder for inhalation and salmeterol and fluticasone propionate inhalation in the treatment of patients with severe COPD effect.Methods90cases of severe COPD patients were selected as the research objects.The control group was treated with salmeterol and fluticasone propionate inhalation,the experimental group was given tiotropium bromide powder for inhalation treatment,18μg,once a day.The clinical indicators such as FEV1,IC and FVC and adverse reactions before and after treatment in two groups were compared and analyzed.Results After treatment,the FEV1of the experimental group was(1.67±0.43)L,significantly higher than that(1.29±0.30)L of the control group(P<0.05).The FVC of the experimental group and the control group were(2.68±0.60)L and(2.28±0.50)L,respectively,and the difference between two groupwas statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was13.3%,significantly lower than24.4%of the control group(P<0.05).Conclusion Compared with salmeterol and fluticasone inhalation,tiotropium bromide powder for inhalationin the treatment for severe COPD patients has more ideal effects and feweradverse reactions.